New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
06:34 EDTALXNAlexion sees FY13 non-GAAP EPS $2.82-$2.92, consensus $2.81
Sees FY13 $1.49B-$1.51B, consensus $1.49B. R&D expenses are expected to be in the range of $285M-$295M, and SG&A expenses in the range of $425M-$435M. The non-GAAP effective tax rate, reported on a cash tax liability basis, is expected to be in the range of 7%-9%.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
05:28 EDTALXNAlexion receives approval for updates to EU label for Solaris
Subscribe for More Information
April 7, 2015
17:38 EDTALXNAlexion CEO Dr. Leonard Bell retired as of March 31
Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use